Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

Jacques Bonneterre(Université Lille Nord de France), Mia von Euler(University Hospital of North Norway), Ignace Vergote(KU Leuven), Beat Thürlimann(University of St.Gallen), Alan Webster(AstraZeneca (United Kingdom)), Maciej Krzakowski(The Maria Sklodowska-Curie National Research Institute of Oncology), J.F.R. Robertson(University of Nottingham), Mark L. Steinberg(AstraZeneca (United Kingdom)), P. Koralewski(Unknown), L. Mauriac(Institut Bergonié)
Journal of Clinical Oncology
November 15, 2000
10.1200/jco.2000.18.22.3748
Cited by 840

Related Papers

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k